Access to Care · Insomnia Care Landscape

The Access Problem in Insomnia Care—and Why It Matters

CBT-I is recommended as first-line care for chronic insomnia, yet many patients never reach it. Health systems can narrow that gap through better identification, multiple evidence-based delivery options, clinical triage, and measurement that includes equity and safety.

By Noctem Health Clinical Team · 10 min read

Updated on October 8, 2026

For chronic insomnia, the central access problem is not a lack of an evidence-based treatment. It is the distance between what guidelines recommend and what routine care can reliably deliver. The American College of Physicians recommends cognitive behavioral therapy for insomnia (CBT-I) as initial treatment for adults with chronic insomnia disorder. The American Academy of Sleep Medicine (AASM) likewise gives multicomponent CBT-I a strong recommendation. Yet a patient who reports months of poor sleep may still encounter a pathway built around brief advice, an over-the-counter product, a medication discussion, or a referral with no available clinician.

That gap matters to health systems because chronic insomnia is common, impairs daytime functioning, and frequently coexists with medical and mental health conditions. A review for clinicians estimates that chronic insomnia disorder affects roughly 6% to 10% of the population, although prevalence varies with the population and definition used. Access should therefore be treated as a population-health and care-delivery issue—not simply as a question of whether a sleep clinic exists.

The relevant access measure is not how many people receive sleep advice. It is how many appropriate patients can start, engage with, and complete evidence-based insomnia care—with a route to more support when needed.

What Evidence-Based Access Actually Means

CBT-I is a structured, multicomponent treatment, not a synonym for sleep hygiene. It commonly combines stimulus control, sleep restriction or sleep-compression procedures, cognitive strategies, and education, supported by sleep diaries and iterative adjustment. In its 2021 guideline, the AASM recommends multicomponent CBT-I and suggests several briefer or single-component behavioral approaches under specified circumstances. The same guideline suggests that sleep hygiene should not be used as a stand-alone treatment for chronic insomnia because the evidence does not support treating education alone as an adequate therapy.

Access also includes competent assessment. Difficulty falling asleep, waking during the night, or waking too early can reflect chronic insomnia, but similar complaints may occur with obstructive sleep apnea, circadian rhythm disorders, restless legs syndrome, medication or substance effects, pain, mood disorders, or another condition. A scalable pathway must identify urgent or complex presentations, evaluate relevant comorbidities, and establish when self-directed treatment is inappropriate or requires closer supervision. Expanding the front door without designing triage and escalation is not the same as expanding care.

Medication remains a clinical option, but not a substitute for access

The access argument should not be reduced to “therapy good, medication bad.” For some patients, medication may be appropriate after assessment, based on symptoms, preferences, prior response, comorbidities, contraindications, and the expected duration of use. The ACP recommends shared decision-making about the benefits, harms, and costs of short-term medication when CBT-I alone has not succeeded. The problem arises when medication becomes the only readily available intervention because the recommended behavioral treatment is operationally out of reach.

Where the Care Pathway Breaks

The shortage and uneven distribution of trained clinicians is real, although frequently quoted counts should be interpreted in context. A 2016 geographic study identified 659 U.S.-based behavioral sleep medicine providers through professional directories and listservs; 105 of 167 U.S. cities with populations above 150,000 had no identified provider. That study was a snapshot based on imperfect directories, not a current workforce census. Its enduring lesson is the maldistribution of expertise: adding a referral order does little when local capacity is absent or wait times, travel, licensing boundaries, or network status make the referral unusable.

Capacity is only one layer. A narrative review of CBT-I dissemination described low referral and utilization even where services existed, alongside limited clinician familiarity, unclear referral routes, and reliance on medication or sleep hygiene. Patients may also face visit costs, time away from work or caregiving, transportation, language barriers, and a treatment schedule that conflicts with shift work. These frictions accumulate: a nominally covered service can remain functionally inaccessible.

• Identification gaps: insomnia symptoms are not consistently assessed, documented, or distinguished from another sleep disorder.
• Knowledge gaps: clinicians and patients may not know what CBT-I includes or how it differs from general sleep tips.
• Supply gaps: trained clinicians may be scarce, geographically concentrated, out of network, or reserved for the most complex referrals.
• Workflow gaps: screening, referral, intake, treatment, progress review, and escalation may sit in disconnected systems.
• Participation gaps: cost, scheduling, language, disability, caregiving, connectivity, and digital literacy can prevent completion even after enrollment.
• Measurement gaps: organizations may count referrals or licenses purchased without measuring starts, adequate treatment exposure, outcomes, or disparities.

No Single Delivery Format Solves Access

CBT-I can be delivered individually or in groups, in person or by telehealth, through briefer protocols, and through digital programs with varying levels of clinician guidance. These are not interchangeable in every patient or setting. They differ in clinical intensity, convenience, staffing, engagement demands, evidence base, and ability to respond when symptoms worsen or the initial formulation is incomplete.

What the digital evidence does—and does not—show

Digital CBT-I is more than a hypothetical scaling strategy. A 2020 meta-analysis of 33 studies involving more than 9,000 randomized participants found greater reductions in Insomnia Severity Index scores with digital CBT-I than with control conditions, with improvement persisting at follow-up. The analysis also found substantial heterogeneity, and the limited direct comparisons favored face-to-face CBT-I by a modest amount. A 2024 component network meta-analysis similarly supported core behavioral and cognitive components while finding that in-person delivery was associated with larger effects in the available evidence.

These findings support digital delivery as an evidence-based option; they do not establish that every sleep app is CBT-I, that every patient will benefit, or that software alone closes the access gap. Programs vary in therapeutic content, study populations, usability, clinician involvement, and regulatory status. Trial efficacy may not reproduce automatically in routine care when enrollment is passive, completion is low, or nobody is responsible for reviewing outcomes.

Equity also requires active design. A mixed-methods study of patient experiences with digital CBT-I identified person-to-person support, autonomy, information burden, functionality, and tailored content as important to engagement. Digital delivery can remove travel and scheduling barriers while creating others, including unreliable internet, limited device access, inaccessible interfaces, low digital or health literacy, and language mismatch. Health systems should preserve a non-digital route and measure uptake and outcomes across demographic and access-relevant groups rather than assuming that an online option is inherently equitable.

A Stepped Care Pathway Can Bridge the Gap Between Patient Need and Provider Capacity

A practical response is a stepped-care architecture: offer an appropriate lower-intensity evidence-based treatment to many patients, monitor response, and reserve higher-intensity clinician care for people who need it. The model is promising but should not be oversold. In a 2025 nonrandomized pragmatic primary-care study, patients chose digital CBT-I, digital CBT-I plus medication, or medication, and nonremitters could select a second step that included face-to-face CBT-I. The digital pathways had better symptom outcomes than medication alone, and face-to-face CBT-I added value for some nonremitters. Because allocation reflected patient preference and the medication-only group was small, the results demonstrate feasibility more clearly than they establish comparative effectiveness.

The “step” should be determined by clinical need and patient preference, not solely by cost. Some patients may reasonably begin with specialist care because of diagnostic uncertainty, severe impairment, safety concerns, significant comorbidity, prior treatment failure, or a need for individualized adaptation. Others may prefer group, brief, telehealth, or digital care. The pathway needs a defined interval for reassessment and a next step that is actually available.

How Health Systems Can Build for Real Access

1. Define the eligible population and entry points. Decide where insomnia is identified—such as primary care, behavioral health, specialty care, or population outreach—and use a validated symptom measure alongside a clinical assessment process.
2. Build triage before scale. Specify exclusions, precautions, diagnostic questions, urgent symptoms, and referral routes for suspected sleep apnea, circadian disorders, movement disorders, unstable psychiatric illness, medication or substance issues, and other conditions requiring evaluation.
3. Offer a portfolio rather than one modality. Combine appropriate digital, group, brief, telehealth, and specialist options so patients are not excluded by geography, schedule, technology, language, disability, or preference.
4. Make ownership explicit. Assign responsibility for outreach, onboarding, diary review when applicable, symptom measurement, nonresponse, adverse experiences, missed engagement, escalation, and communication with the broader care team.
5. Create a stepped-care rule. Establish when to continue, add support, switch formats, conduct further assessment, or refer to a specialist. Do not let an automated program become a dead end.
6. Measure the full funnel. Track identification, referral, enrollment, treatment start, meaningful participation, completion, symptom change, patient-reported functioning, escalation, and time to care—not only the number of accounts created.
7. Audit for inequity and burden. Stratify access and outcomes where appropriate, assess patient costs and staff workload, and use the findings to revise outreach, language access, technical support, and alternatives to digital care.

Choose outcomes that reveal whether access improved

A successful program should shorten time to an appropriate treatment without trading away clinical quality. Useful measures include the proportion of screen-positive patients who receive further assessment, days from identification to treatment start, treatment engagement, change on a validated insomnia measure, patient-reported daytime function, and the proportion needing a higher level of care. Balancing measures should include clinician workload, dropout, unintended delays in evaluating another sleep disorder, and patient-reported usability.

Equity measures belong in the core dashboard. Compare offer, start, engagement, completion, and outcome rates by factors relevant to the population and legally appropriate to analyze, such as language, rurality, insurance, age, race and ethnicity, disability, and digital access. A pathway that expands total volume while widening completion or outcome gaps has improved reach, but not equitable access.

The Goal Is a Dependable Clinical Care Pathway

The insomnia access problem will not be solved by asking every specialist to see more patients, nor by placing an unguided app in front of everyone. It requires a system that recognizes chronic insomnia, offers authentic CBT-I in more than one usable format, preserves assessment and clinical judgment, and escalates care when the first approach is insufficient. Digital and asynchronous tools can be important parts of that system, especially when they extend rather than erase clinician capacity.

For health system leaders, the strategic question is therefore not simply whether to purchase or launch a sleep intervention. It is whether the organization can build a reliable route from symptom identification to the right level of evidence-based care—and demonstrate that patients can actually travel that route.